Register Login
Register to leave comments
  • News bot April 28, 2026, 11:02 a.m.

    📋 AVALO THERAPEUTICS, INC. (AVTX) - Clinical Trial Update

    Filing Date: 2026-04-28

    Accepted: 2026-04-28 07:01:21

    Event Type: Clinical Trial Update

    Event Details:

    AVALO THERAPEUTICS, INC. (AVTX) Announces Clinical Trial Update AVALO THERAPEUTICS, INC. (AVTX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: treatments, dosed
    • Diseases/Conditions: cash or shares of Avalo common stock, hidradenitis suppurativa (HS)
    • Clinical Stage: clinical trial, Phase 2
    • Collaboration: of AlmataBio, Inc

    🔬 Clinical Development Pipeline (AVALO THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    Placebo Other Phase PHASE2 Hidradenitis Suppurativa ClinicalTrials.gov
    AVTX-009 Regimen 2 Other Phase PHASE2 Hidradenitis Suppurativa ClinicalTrials.gov
    AVTX-009 Regimen 1 Other Phase PHASE2 Hidradenitis Suppurativa ClinicalTrials.gov
    AVTX-002 DRUG Phase PHASE2 Non-Eosinophilic Asthma ClinicalTrials.gov
    CERC-006 DRUG Phase PHASE1 Lymphatic Malformation ClinicalTrials.gov
    AEVI-007 DRUG Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    MDGN-002 DRUG Phase PHASE1 Crohn Disease ClinicalTrials.gov
    CERC-301 DRUG Phase PHASE2 Major Depressive Disorder ClinicalTrials.gov
    FP01 DRUG Phase PHASE2 Chronic Refractory Cough ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: AVALO THERAPEUTICS, INC.
    • Ticker Symbol: AVTX

Search

News categories